SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

I

	is box if no longer subje L6. Form 4 or Form 5	ct to STATE	MENT OF CHANGES IN BENEFICIAL	OMB Number: 323 Estimated average burden		
obligation Instructio	ns may continue. <i>See</i> on 1(b).		Filed pursuant to Section 16(a) of the Securities Exchange A or Section 30(h) of the Investment Company Act of 19		hours per response:	
1. Name and Address of Reporting Person*			2. Issuer Name <b>and</b> Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VSTA]	5. Relationship of (Check all applica	Reporting Person(s) to Issuer	
<u>SAXE JON S</u>				X Director	10% Owne	
				Officer (	give title Other (spe	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	below)	below)	

OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

SAXE JON S (Last) C/O VISTAGE	(First)	[		Gen Therape of Earliest Transac 2015				(Checl X	k all applicable) Director Officer (give title below)	10% ( Other below	(specify		
343 ALLERTO	N AVENUE		4	4. If Am	nendment, Date of (	Driginal	Filed	(Month/Day/Y	'ear)	6. Indi Line)	vidual or Joint/Grou	p Filing (Check A	pplicable
(Street) SOUTH SAN FRANCISCO	CA	94080								X	Form filed by On Form filed by Mo Person		
(City)	(State)	(Zip)											
		Table I - No	n-Derivati	ive S	ecurities Acqu	uired,	Dis	posed of, o	or Ben	eficially	Owned		
1. Title of Security (Instr. 3) Date (Month/E					2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
		Table II -			curities Acqui lls, warrants, o						wned		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant for Common Stock	\$10	01/11/2015		A		20,000		01/11/2015	01/11/2020	Common Stock	20,000	\$0	20,000	D	

Explanation of Responses:

/s/ Jerrold Dotson, Attorney-in-01/13/2015

Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.